StockData
Actuate Therapeutics, Inc. logo

Actuate Therapeutics, Inc. (ACTU) stock

ACTUNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 0/30
$0.21−0.03 (-12.95%)

Close on Nov 19, 2026Market cap $5.13MP/E –Yield –

Actuate Therapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

No gross profit figures for Actuate Therapeutics

Actuate Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Actuate Therapeutics figures

See a number that looks wrong?